Cargando…
Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection
INTRODUCTION: Clinical trials have demonstrated the efficacy of FMT for reduction in CDI recurrences (rCDI), but this treatment and its reporting in the literature has significant heterogeneity. Recent publications (e.g., Ramai et al. in Dig Dis Sci 2020. https://doi.org/10.1007/s10620-020-06185-7)...
Autores principales: | Feuerstadt, Paul, Aroniadis, Olga C., Svedlund, Felicia L., Garcia, Mariana, Stong, Laura, Boules, Mena, Khanna, Sahil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236970/ https://www.ncbi.nlm.nih.gov/pubmed/34275058 http://dx.doi.org/10.1007/s10620-021-07141-9 |
Ejemplares similares
-
Clinical complications in patients with primary and recurrent Clostridioides difficile infection: A real-world data analysis
por: Feuerstadt, Paul, et al.
Publicado: (2021) -
2432. Durability Against Antibiotics After Response to Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection
por: Saha, Srishti, et al.
Publicado: (2019) -
Safety of fecal microbiota, live-jslm (REBYOTA(™)) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials
por: Lee, Christine, et al.
Publicado: (2023) -
Safety of fecal microbiota transplantation for Clostridioides difficile infection focusing on pathobionts and SARS-CoV-2
por: Yadav, Devvrat, et al.
Publicado: (2021) -
Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls
por: Sandhu, Avnish, et al.
Publicado: (2021)